PhaseBio Pharmaceuticals Inc

NASDAQ:PHAS   3:57:32 PM EDT
0.85
+0.04 (+4.41%)
Earnings Announcements

Phasebio Pharmaceuticals Reports Fourth Quarter And Full-Year 2021 Financial Results And Provides Recent Business Highlights

Published: 03/24/2022 20:38 GMT
PhaseBio Pharmaceuticals Inc (PHAS) - Phasebio Pharmaceuticals Reports Fourth Quarter and Full-year 2021 Financial Results and Provides Recent Business Highlights.
Phasebio Pharmaceuticals Inc - Qtrly Loss per Share $0.90.
Revenue is expected to be $0.83 Million
Adjusted EPS is expected to be -$0.40

Next Quarter Revenue Guidance is expected to be $8.13 Million
Next Quarter EPS Guidance is expected to be -$0.36

More details on our Analysts Page.